Page 13 - Structural Heart Program News Today

WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.There was also no difference between the edoxaban (Savaysa, Daiichi Sankyo) and DAPT groups in cerebral thromboembolism and neurological or neurocognitive function,

It's time again to check the pulse — of Florida health care policy and politics.

PASCAL device safe and linked to symptom improvement in severe tricuspid regurgitation

The ADAPT-TAVR trial showed a numerical reduction in leaflet thrombosis with edoxaban versus dual antiplatelet therapy, but no reduction in cerebral events or neurocognitive function

A roundup of important career moves and accomplishments among physicians.

February Heart Health Month means it’s the perfect time to focus on keeping that all-important muscle in your body healthy. Including how to fix it when it gets… broken.

Within minutes of arriving at The Valley Hospital, Albert was moved into the cardiac catheterization laboratory where imaging revealed that Albert had critical blockages in all three major arteries of the heart

Study may change the way we manage patients with moderate aortic stenosis and save lives

Ascension Providence is the first in Texas to be recognized through the Edwards Benchmark program for aortic stenosis treatment.

Structural heart disease occurs from aging, injury or infection and most often affects the heart valves. As the heart beats, a precisely timed series of opening and closing of valves keeps blood flowing in the right direction. All four valves — aortic, mitral, tricuspid and pulmonic — need to open wide, then shut tight in rhythm. Heart valves may not close all the way (regurgitation) or open sufficiently (stenosis). These conditions can develop over time and often don’t need treatment. So...